Modification of CAR-T cells
US12419913B2 · kind B2 · utility
0Cited by
8References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 20, 2023 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Mar 20, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/7051
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.